FORT LAUDERDALE, FL — (Marketwired) — 01/12/17 — A1 Group, Inc. (OTC PINK: AWON) is pleased to announce that it has signed a global master licensing and distribution agreement ?with Delaware-based Novaceutical Sciences, Inc. (NSI). NSI is a company focused on unique delivery systems within the nutraceutical and pharmaceutical industries. NSI–s primary focus has been on nasal delivery across various categories.
Nasal delivery systems are an exceedingly effective way for delivering even complex molecules across the epithelial cell layer that covers the nasal cavity. This allows for systemic blood circulation without hepatic and intestinal metabolism and systemic delivery can be achieved within five minutes for smaller molecules. Accordingly, nasal administration provides rapid delivery and avoids the degradation of compounds in the gut and liver which is often seen with oral administration of pills and capsules.
The Novaceutical Sciences patent pending technology is focused on providing intranasal and pulmonary delivery of vitamin and essential trace mineral nutrients. Typically, vitamins and trace minerals are delivered orally in tablets, capsules and gummies. Previous to the NSI technology, oral delivery has been the major challenge for essential mineral bioavailability. The intranasal system can even achieve delivery to the brain through the blood-brain barrier. Areas of treatment include: energy, memory, sexual health, neuro-protection and repair, anti-anxiety and others. Specific nutrients can be selected to enhance formulations suitable for different market verticals. Additionally, the “no drip” metered-dose inhaler (MDI) device technology being utilized assures no runoff, post nasal drip or messy “wet” priming.
Over the next several weeks the company will be filing a name and symbol change to better reflect the new direction of the company. The company will also be releasing specific product categories over the next several weeks.
A1 Group, Inc. was set up to invest in vaping technologies. A1 Group invests in or partners with companies that develop innovative technologies for creating smoke-free inhalation delivery systems, which utilize Electronic Vapor Devices that can be adapted to deliver a variety of substances, including e-liquids (with or without nicotine,) aroma therapy, CBD–s, hemp, cannabis oils, wax and extracts and herbs. These Smoke-free delivery systems offer a safer alternative to traditional cigarettes and pipes, as well as. A1 has engaged a proven and prolific research team that has previously discovered and introduced to the market many of the best-known nutritional supplements on the market today, geared towards driving significant value to the shareholders. A1 targets companies with a seasoned management team that have been actively involved in creating nutritional solutions to current health challenges, and have a history of successful development in the supplements and nutraceuticals production industry.
This press release may contain certain “forward-looking statements” relating to the business of A1 Group Inc. All statements, other than statements of historical fact included herein are “forward-looking statements,” including any other statements of non-historical information. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company–s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company–s periodic reports that are filed with the Securities and Exchange Commission and available on its website (). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Steve Bryant
Vice President of Investor Relations
954-440-4678
You must be logged in to post a comment Login